Table 1.
Radiomics studies in NSCLC, categorized into sections based on their investigated endpoint. The Data column specifies the total number of patients involved in the study, in brackets split by training and validation cohorts if applicable and specifying other cancer types of cohorts if applicable. Note: Studies marked with * are validation studies and their RQS score components refer to methodology based on the previous published data. This table has been simplified to clarify presentation – more details for each study are available in Supplementary Table 2.
| Reference | NSCLC stage | Data (training + validation) | Radiomic features in final model | Result |
|---|---|---|---|---|
| Overall survival | ||||
| Aerts et al. 2014 [13] | 1−3b | 647 pCT (422 + 225) |
Shape, first order and texture | CI = 0.65 |
| Van Timmeren et al. 2017 [14]* | 1−4 | 252 pCT and CBCT (102 + 56 + 94) |
Shape, first order and texture | CI = 0.69, 0.61, 0.59 (pCT) CI = 0.66,0.63,0.59 (CBCT) |
| Grossman et al. 2017 [15]* | 1−3 | 351 diagnostic CT (262 + 89) |
Shape, first order and texture | CI = 0.60 |
| Grossman et al. 2017 [15] | 1−3 | 351 diagnostic CT (262 + 89) |
Not specified | CI = 0.61 |
| Yu et al. 2017 [16] | 1 | 442 diagnostic CT (147 + 295) |
First order and texture | CI = 0.64 |
| Chaddad et al. 2017 [17] | 1−3b | 315 pCT | Shape and texture | Average AUC = 0.70−0.76 |
| Fave et al. 2017 [18] | 3 | 107 4DCT end of exhale, pCT and CBCT | Shape and texture | CI = 0.672 |
| Li et al. 2017 [19] | 1−2a | 59 follow up CT | Texture | AUC = 0.81 |
| Li et al. 2017 [20] | 1−2a | 92 4DCT Average-CT or 50 % phase-CT |
Shape and first order | AUC = 0.728 |
| Tang et al. 2018 [21] | 1−3 | 290 staging CT (114 + 176) |
Shape, first order and texture | CI = 0.72 |
| Bianconi et al. 2018 [22] | 1−3 | 203 pCT | Shape and texture | HR = 1.06−1.48 |
| De Jong et al. 2018 [23]* | 4 | 195 diagnostic CT | Shape, first order and texture | CI = 0.576 |
| Lee et al. 2018 [24] | 1−3 | 339 CT | Shape, first order and texture | CI = 0.772 |
| He et al. 2018 [25] | 1−3 | 186 CT (298 after oversampling (223 + 75)) |
Not specified | AUC = 0.9296 |
| Starkov et al. 2018 [26] | 1 | 116 pCT | Texture | High risk vs low risk median p-values = 0.04–0.07 |
| Yang et al. 2018 [27] | 1−4 | 371 CT (239 + 132) |
First order and texture | CI = 0.702 |
| Wang et al. 2019 [28] | 3 | 70 pre-treatment and 97 post-treatment CT from 118 patients | Texture | CI = 0.743 |
| Shi et al. 2019 [29] | 3 | 11 CBCT from 23 patients | First order | HR = 0.21 |
| Van Timmeren et al. 2019 [30] | 1−4 | 337 pCT and 2154 CBCTs from 337 patients (141 + 94 + 61 + 41) |
First order and texture | CI = 0.59, 0.54, 0.57 |
| Huang et al. 2019 [31] | 1−4 | 371 CT (254 + 63 + 54) |
Shape, first order and texture | CI = 0.621, 0.649 |
| Franceschini et al. 2019 [32] | 1−2 | 102 4DCT start of inspiration (70 + 32) |
Shape and texture | AUC = 0.85 |
| Local or metastatic recurrence | ||||
| Coroller et al. 2015 [33] | 2−3 | 182 pCT (98 + 84) |
First order and texture | CI = 0.6 |
| Mattonen et al. 2016 [34] | 1 | 45 follow-up CT | First order and texture | AUC = 0.85 |
| Huynh et al. 2016 [35] | 1−2 | 113 CT | First order and texture | Median CI = 0.67 |
| Huynh et al. 2017 [36] | 1−2a | 112 CT and AIP CT | Shape, first order and texture | AIP radiomics CI = 0.667 FB radiomics CI = 0.601 |
| Fave et al. 2017 [18] | 3 | 107 4DCT end of exhale, pCT and CBCT | Shape and texture | CI = 0.632, 0.558 (DM, LRR) |
| Li et al. 2017 [19] | 1−2a | 59 follow up CT | Texture | AUC = 0.80, 0.80 (RFS, LR-RFS) |
| Li et al. 2017 [20] | 1−2a | 92 4DCT Average-CT or 50 % phase-CT |
Shape | AUC = 0.747, 0.690 (RFS, LL-RFS) |
| Dou et al. 2018 [37] | 2−3 | 200 pCT (100 + 100) |
Texture | CI = 0.65 |
| Ferreira Junior et al. 2018 [38] | 1−4 | 68 CT (52 + 16) |
Shape and texture | AUC = 0.75, 0.71 (lymph node metastasis, DM) |
| Yang et al. 2018 [39] | 1−3 | 159CT (106 + 53) |
Shape, first order and texture | AUC = 0.856 |
| Zhong et al. 2018 [40] | 1−2 | 492 CT | First order and texture | AUC = 0.972 |
| Lafata et al. 2019 [41] | 1 | 70 CT | Texture | Maximum AUC = 0.72, 0.83, 0.60 (recurrence, LR, non-LR) |
| Akinci D’Antonoli et al. 2019 [42] | 1−2b | 124 CT | Shape, first order and texture | AUC 0.731, 0.750 (LR, DM) |
| He et al. 2019 [43] | Not specified | 717CT (423 + 294) |
First order and texture | CI = 0.734 |
| Xu et al. 2019 [44] | 3−4 | 132 CT (106 + 26) |
Texture | AUC = 0.642 |
| Franceschini et al. 2019 [32] | 1−2 | 102 4DCT start of inspiration (70 + 32) |
Shape, first order and texture | AUC = 0.73 |
| Ferreira-Junior et al. 2019 [45] | 1−4 | 85 CT | Shape, first order and texture | AUC = 0.92, 0.84 (DM, nodal metastasis) |
| Cong et al. 2019 [46] | 1a | 649 venous phase CT (455 + 194) |
Shape, first order and texture | AUC = 0.851 |
| Treatment response, disease-free or progression-free survival | ||||
| Coroller et al. 2016 [47] | 2−3 | 127 pCT | Shape, first order and texture | Median AUC = 0.65, 0.61 (GRD, pCR) |
| Huang et al. 2016 [48] | 1−2 | 282 CT (141 + 141) | First order and texture | HR = 2.09 |
| Song et al. 2016 [49] | 1−4 | 152 CT (80 + 72) |
Texture | HR = 2.35, 2.75 |
| Coroller et al. 2017 [50] | 2−3 | 85 pCT | Shape, first order and texture | Median AUC = 0.68, = 0.71 (pCR, GRD) |
| Tunali et al. 2019 [51] | 3b-4 | 228 CT | Texture | AUC = 0.804 |
| Franceschini et al. 2019 [32] | 1−2 | 102 4DCT start of inspiration (70 + 32) |
Texture | AUC = 0.88 |
| Lung toxicity | ||||
| Moran et al. 2017 [52] | 1 | 14 diagnostic CT | First order and texture | AUC = 0.689−0.750 |
| Krafft et al. 2018 [53] | Not specified | 192 50 % 4DCT phase | First order and texture | Average AUC = 0.68 |
| Staging | ||||
| Yuan et al. 2018 [54] | 1 | 327 CT | First order and texture | AUC = 0.938 |
| Yang et al. 2019 [55] | 1−3 | 256 CT | First order and texture | AUC = 0.93 |
Abbreviations: AUC, area under the curve; CBCT, cone-beam CT; CI, concordance index; DFS, disease free survival; DM, distant metastasis; GRD, gross residual disease; H&N, head and neck; HR, hazard ratio; LR, local relapse; LRR, local regional recurrence; LR-RFS, loco-regional recurrence-free survival; OS, overall survival; pCR, pathological complete response; pCT, radiotherapy planning CT scan; PFS, progression free survival; RFS, recurrence free survival.